163 related articles for article (PubMed ID: 8642047)
1. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers.
Hamada M; Fujiwara T; Hizuta A; Gochi A; Naomoto Y; Takakura N; Takahashi K; Roth JA; Tanaka N; Orita K
J Cancer Res Clin Oncol; 1996; 122(6):360-5. PubMed ID: 8642047
[TBL] [Abstract][Full Text] [Related]
2. Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer.
Shimoyama S; Konishi T; Kawahara M; Aoki F; Harada N; Shimizu S; Murakami T; Kaminishi M
Hepatogastroenterology; 1998; 45(23):1497-504. PubMed ID: 9840093
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene.
Seta T; Imazeki F; Yokosuka O; Saisho H; Suzuki T; Koide Y; Isono K
Dig Dis Sci; 1998 Feb; 43(2):279-89. PubMed ID: 9512119
[TBL] [Abstract][Full Text] [Related]
4. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
[TBL] [Abstract][Full Text] [Related]
5. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
Craanen ME; Blok P; Offerhaus GJ; Meijer GA; Dekker W; Kuipers EJ; Meuwissen SG
J Pathol; 1999 Dec; 189(4):481-6. PubMed ID: 10629547
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
Slebos RJ; Baas IO; Clement M; Polak M; Mulder JW; van den Berg FM; Hamilton SR; Offerhaus GJ
Br J Cancer; 1996 Jul; 74(2):165-71. PubMed ID: 8688317
[TBL] [Abstract][Full Text] [Related]
7. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas.
Seong J; Chung EJ; Kim H; Kim GE; Kim NK; Sohn SK; Min JS; Suh CO
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1167-73. PubMed ID: 10613309
[TBL] [Abstract][Full Text] [Related]
8. Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy.
Sogawa N; Takiguchi N; Koda K; Oda K; Satomi D; Kato K; Ishikura H; Miyazaki M
Int J Oncol; 2002 Oct; 21(4):787-93. PubMed ID: 12239617
[TBL] [Abstract][Full Text] [Related]
9. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis.
Liu XP; Tsushimi K; Tsushimi M; Kawauchi S; Oga A; Furuya T; Sasaki K
Cancer Lett; 2001 Sep; 170(2):183-9. PubMed ID: 11463497
[TBL] [Abstract][Full Text] [Related]
10. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
[TBL] [Abstract][Full Text] [Related]
11. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Mitani Y; Oue N; Hamai Y; Aung PP; Matsumura S; Nakayama H; Kamata N; Yasui W
J Pathol; 2005 Jan; 205(1):65-73. PubMed ID: 15586362
[TBL] [Abstract][Full Text] [Related]
12. [Clinical implication of p53 analysis on DNA-damaging therapies of human gastric and rectal cancers].
Fujiwara T; Tanaka N; Hizuta A; Gochi A; Hamada M; Takahashi K; Takakura N; Orita K
Gan To Kagaku Ryoho; 1996 Jul; 23(8):1081-3. PubMed ID: 8687227
[No Abstract] [Full Text] [Related]
13. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
Kondo S; Barna BP; Kondo Y; Tanaka Y; Casey G; Liu J; Morimura T; Kaakaji R; Peterson JW; Werbel B; Barnett GH
Oncogene; 1996 Sep; 13(6):1279-85. PubMed ID: 8808702
[TBL] [Abstract][Full Text] [Related]
14. Analysis of p53, p21(Waf1/Cip1) and TGF-beta(3) immunohistochemical staining in Bowen's disease.
Kawakami T; Soma Y; Mizoguchi M; Saito R
Dermatology; 2001; 202(1):9-15. PubMed ID: 11244221
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Fan S; el-Deiry WS; Bae I; Freeman J; Jondle D; Bhatia K; Fornace AJ; Magrath I; Kohn KW; O'Connor PM
Cancer Res; 1994 Nov; 54(22):5824-30. PubMed ID: 7954409
[TBL] [Abstract][Full Text] [Related]
16. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
17. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
Kralj M; Husnjak K; Körbler T; Pavelić J
Cancer Gene Ther; 2003 Jun; 10(6):457-67. PubMed ID: 12768191
[TBL] [Abstract][Full Text] [Related]
18. Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer.
Hosaka N; Ichikawa Y; Ishikawa T; Nagashima Y; Kunisaki C; Takahashi M; Moriwaki Y; Akiyama H; Yamaguchi S; Ota M; Ooki S; Ike H; Shimada H
Anticancer Res; 2001; 21(1A):229-35. PubMed ID: 11299739
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy.
Charara M; Edmonston TB; Burkholder S; Walters R; Anne P; Mitchell E; Fry R; Boman B; Rose D; Fishel R; Curran W; Palazzo J
Anticancer Res; 2004; 24(5B):3161-7. PubMed ID: 15510606
[TBL] [Abstract][Full Text] [Related]
20. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
